FDA
-
-
-
-
-
-
-
Sierra Oncology Inc (SRRA) PT Raised to $51 at H.C. Wainwright
-
-
-
-
-
-
-
Sierra Oncology Updates Topline Data Timing for Pivotal Phase 3 Trial of Momelotinib in Myelofibrosis
-
-
-
-
-
-
-
Sierra Oncology Reports First Quarter 2021 Results
-
-
-
-
-
-
-
Sierra Oncology Strengthens Management Team to Implement North American Pre-Commercialization Strategy for Momelotinib
-
-
-
-
-
-
-
Sierra Oncology Appoints Dr. Stephen Dilly as President and Chief Executive Officer
-
-
-
-
-
-
-
Sierra Oncology Completes Conversion of Preferred to Common Stock and Issues Stock to Gilead
-
-
-
-
-
-
-
Sierra Oncology Launches the MOMENTUM Phase 3 Clinical Trial for Patients with Myelofibrosis
-
251,410 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All